Affiliation:
1. College of Pharmaceutical Science, Key Laboratory of Pharmaceutical Quality Control of Hebei province, Hebei University, Baoding 071002, China
2. College of Life Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Hebei University, Baoding 071002, China
3. Affiliated Hospital of Hebei University, Baoding 071002, China
Abstract
Background:
In our previous study, we have isolated a new compound, named Fumosorinone (FU)
from insect pathogenic fungi, and was found to inhibit proliferation, migration, and invasion of breast cancer
MDA-MB-231 cells.
Objective:
The aim of this study was to identify the underlying molecular mechanisms for FU effects on MDAMB-
231 cells.
Methods:
After MDA-MB-231 cells were treated with FU for 48h, RNA sequencing was used to identify the
effect of FU on the transcriptome of MDA-MB-231 cells. The validation of the relative expression of the selective
genes was done using quantitative real-time PCR (qRT-PCR).
Results:
The transcriptome results showed that 2733 genes were differentially expressed between the untreated
and the FU-treated cells, including 1614 up-regulated and 1119 down-regulated genes. The multiple genes are
associated with cancer cell growth, migration, and invasion. Functional analysis identified multitude of pathways
related to cancer, such as cell cycle, ECM–receptor interaction, p53 signaling pathway. We selected 4
upregulated and 9 downregulated genes, which are associated with breast cancer to verify their expression using
qRT-PCR. The validation showed that HSD3B1, ALOX5, AQP5, COL1A2, CCNB1, CCND1, VCAM-1,
PTPN1 and PTPN11 were significantly downregulated while DUSP1, DUSP5, GADD45A, EGR1 were upregulated
in FU-treated MDA-MB-231cells.
Conclusion:
These aberrantly expressed genes and pathways may play pivotal roles in the anti-cancer activity of
FU, and maybe potential targets of FU treatments for TNBC. Further investigations are required to evaluate the
FU mechanisms of anti-cancer action in vivo.
Funder
National Key Research and Development Program of China
National Natural Science Foundation of China
Changjiang Scholars and Innovative Research Team in University
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Pharmacology,Molecular Medicine
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献